Whitehawk Therapeutics Q1 net loss beats estimates

Whitehawk Therapeutics

07/05/2026 13:13

Overview

US oncology therapeutics firm's Q1 net loss narrowed, beating analyst expectations

Q1 operating loss was smaller than analysts expected

Company ended Q1 with $123 mln in cash and investments, funding expected into 2028

Outlook

Whitehawk expects to submit IND for HWK-206 in mid-2026; Phase 1 recruitment in Q3 2026

Whitehawk expects cash and investments to fund operations into 2028

Result Drivers

HIGHER R&D SPENDING - Increased research and development expenses driven by ongoing Phase 1 trials and milestone payments under license agreement

Company press release: ID:nPn96NXcRa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
Beat
-$22.19 mln
-$24.71 mln (4 Analysts)
Q1 Operating Income
Beat
-$23.52 mln
-$25.22 mln (5 Analysts)
Q1 Operating Expenses
$23.52 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Whitehawk Therapeutics Inc is $6.50, about 56.6% above its May 6 closing price of $4.15

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)